The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Regeneron Pharmaceuticals Inc

Nasdaq: REGN
Last

(U.S.) $369.95

Today's change-7.78 -2.06%
Updated May 6 4:00 PM EDT. Delayed by at least 15 minutes.
 

Regeneron Pharmaceuticals Inc

Nasdaq: REGN
Last

(U.S.) $369.95

Today's change-7.78 -2.06%
Updated May 6 4:00 PM EDT. Delayed by at least 15 minutes.

Regeneron Pharmaceuticals Inc down (U.S.)$7.78

Regeneron Pharmaceuticals Inc closed sharply lower Friday, dropping (U.S.)$7.78 or 2.06% to (U.S.)$369.95. Over the last five days, shares have lost 1.79% and are down 31.85% for the last year to date. This security has underperformed the S&P 500 by 20.18% during the last year.

Key company metrics

  • Open(U.S.) $376.36
  • Previous close(U.S.) $377.73
  • High(U.S.) $377.43
  • Low(U.S.) $365.93
  • Bid / Ask(U.S.) $355.01 / (U.S.) $370.05
  • YTD % change-31.85%
  • Volume884,777
  • Average volume (10-day)841,534
  • Average volume (1-month)953,504
  • Average volume (3-month)975,666
  • 52-week range(U.S.) $348.96 to (U.S.) $605.93
  • Beta1.07
  • Trailing P/E58.75×
  • P/E 1 year forward32.94×
  • Forward PEG1.59×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $6.30
Updated May 6 4:00 PM EDT. Delayed by at least 15 minutes.
S&P TSX0.51%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2015Q3/2015Q2/2015Q1/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015
Revenue1,0981,137999870
Total other revenue--------
Total revenue1,0981,137999870
Gross profit9871,028910786
Total cost of revenue1111098984
Total operating expense869745670587
Selling / general / administrative295210175159
Research & development461426390343
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)20161
Other operating expenses, total--------
Operating income229392329283
Interest income (expense), net non-operating-4-2-3-6
Gain (loss) on sale of assets--------
Other--------
Income before tax227393328277
Income after tax15521019576
Income tax, total72183133201
Net income15521019576
Total adjustments to net income--------
Net income before extra. items15521019576
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items15521019576
Inc. avail. to common incl. extra. items15521019576
Diluted net income15521019576
Dilution adjustment0------
Diluted weighted average shares115116115115
Diluted EPS excluding extraordinary itemsvalue per share1.341.811.690.66
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share1.351.811.770.67